Deslorelin

Drug Profile

Deslorelin

Alternative Names: D-Trp-LHRH-PEA; LHRH agonist analogue; Somagard

Latest Information Update: 03 Aug 2006

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Shire Pharmaceuticals Group
  • Class Antineoplastics; Hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Endometriosis; Polycystic ovary syndrome; Precocious puberty; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 10 Mar 2003 A study has been added to the Endocrine disorders therapeutic trials section
  • 15 Feb 2001 Discontinued-III for Prostate cancer in Europe (IV-injection)
  • 22 Jun 2000 Discontinued-Clinical for Uterine leiomyoma in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top